Literature DB >> 15591008

Delaying the mitochondrial decay of aging with acetylcarnitine.

Bruce N Ames1, Jiankang Liu.   

Abstract

Oxidative mitochondrial decay is a major contributor to aging. Some of this decay can be reversed in old rats by feeding them normal mitochondrial metabolites, acetylcarnitine (ALC) and lipoic acid (LA), at high levels. Feeding the substrate ALC with LA, a mitochondrial antioxidant, restores the velocity of the reaction (K(m)) for ALC transferase and mitochondrial function. The principle appears to be that, with age, increased oxidative damage to protein causes a deformation of structure of key enzymes with a consequent lessening of affinity (K(m)) for the enzyme substrate. The effect of age on the enzyme-binding affinity can be mimicked by reacting it with malondialdehyde (a lipid peroxidation product that increases with age). In old rats (vs. young rats), mitochondrial membrane potential, cardiolipin level, respiratory control ratio, and cellular O(2) uptake are lower; oxidants/O(2), neuron RNA oxidation, and mutagenic aldehydes from lipid peroxidation are higher. Ambulatory activity and cognition decline with age. Feeding old rats ALC with LA for a few weeks restores mitochondrial function; lowers oxidants, neuron RNA oxidation, and mutagenic aldehydes; and increases rat ambulatory activity and cognition (as assayed with the Skinner box and Morris water maze). A recent meta-analysis of 21 double-blind clinical trials of ALC in the treatment of mild cognitive impairment and mild Alzheimer's disease showed significant efficacy vs. placebo. A meta-analysis of 4 clinical trials of LA for treatment of neuropathic deficits in diabetes showed significant efficacy vs. placebo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15591008     DOI: 10.1196/annals.1320.010

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  31 in total

1.  Age-dependent and tissue-related glutathione redox status in a mouse model of Alzheimer's disease.

Authors:  Cheng Zhang; Cynthia Rodriguez; James Spaulding; Tak Yee Aw; June Feng
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

Review 3.  Novel therapeutics for Alzheimer's disease: an update.

Authors:  David J Bonda; Hyun-Pil Lee; Hyoung-gon Lee; Avi L Friedlich; George Perry; Xiongwei Zhu; Mark A Smith
Journal:  Curr Opin Drug Discov Devel       Date:  2010-03

Review 4.  Supplemental substances derived from foods as adjunctive therapeutic agents for treatment of neurodegenerative diseases and disorders.

Authors:  Gregory E Bigford; Gianluca Del Rossi
Journal:  Adv Nutr       Date:  2014-07-14       Impact factor: 8.701

5.  Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel.

Authors:  W H Xiao; H Zheng; G J Bennett
Journal:  Neuroscience       Date:  2011-12-20       Impact factor: 3.590

Review 6.  Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatment strategies.

Authors:  David J Bonda; Xinglong Wang; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

7.  Mitochondrial Dysfunction during Brain Aging: Role of Oxidative Stress and Modulation by Antioxidant Supplementation.

Authors:  Sasanka Chakrabarti; Soumyabrata Munshi; Kalpita Banerjee; Ishita Guha Thakurta; Maitrayee Sinha; Maria Bindu Bagh
Journal:  Aging Dis       Date:  2011-03-23       Impact factor: 6.745

8.  Frontiers in Alzheimer's disease therapeutics.

Authors:  Jeremy G Stone; Gemma Casadesus; Kasia Gustaw-Rothenberg; Sandra L Siedlak; Xinglong Wang; Xiongwei Zhu; George Perry; Rudy J Castellani; Mark A Smith
Journal:  Ther Adv Chronic Dis       Date:  2011-01-01       Impact factor: 5.091

9.  A prospective, proof-of-concept investigation of KPAX002 in chronic fatigue syndrome.

Authors:  Jon D Kaiser
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 10.  Mitochondrial death effectors: relevance to sarcopenia and disuse muscle atrophy.

Authors:  Emanuele Marzetti; Judy C Y Hwang; Hazel A Lees; Stephanie E Wohlgemuth; Esther E Dupont-Versteegden; Christy S Carter; Roberto Bernabei; Christiaan Leeuwenburgh
Journal:  Biochim Biophys Acta       Date:  2009-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.